Format

Send to

Choose Destination
Ophthalmology. 2015 May;122(5):874-81. doi: 10.1016/j.ophtha.2015.01.002. Epub 2015 Feb 9.

A randomized trial of levodopa as treatment for residual amblyopia in older children.

Author information

1
Wilmer Ophthalmological Institute, Johns Hopkins University, Baltimore, Maryland. Electronic address: pedig@jaeb.org.
2
Jaeb Center for Health Research, PEDIG Coordinating Center, Tampa, Florida.
3
Dean McGee Eye Institute, University of Oklahoma, Oklahoma City, Oklahoma.
4
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.
5
Pediatric Ophthalmology and Adult Strabismus PA, Dallas, Texas.
6
Department of Ophthalmology, Nationwide Children's Hospital, Columbus, Ohio.
7
Houston Eye Associates, The Woodlands, Texas.
8
Pediatric Eye Associates, Wilmette, Illinois.
9
Duke Eye Center, Durham, North Carolina.

Abstract

OBJECTIVE:

To assess the efficacy and short-term safety of levodopa as adjunctive treatment to patching for amblyopia.

DESIGN:

Randomized, placebo-controlled trial.

PARTICIPANTS:

One hundred thirty-nine children 7 to 12 years of age with residual amblyopia resulting from strabismus, anisometropia, or both combined (visual acuity [VA], 20/50-20/400) after patching.

METHODS:

Sixteen weeks of oral levodopa or placebo administered 3 times daily while patching the fellow eye 2 hours daily.

MAIN OUTCOME MEASURES:

Mean change in best-corrected amblyopic-eye VA at 18 weeks.

RESULTS:

At 18 weeks, amblyopic-eye VA improved from randomization by an average of 5.2 letters in the levodopa group and by 3.8 letters in the placebo group (difference adjusted for baseline VA, +1.4 letters; 1-sided P=0.06; 2-sided 95% confidence interval, -0.4 to 3.3 letters). No serious adverse effects from levodopa were reported during treatment.

CONCLUSIONS:

For children 7 to 12 years of age with residual amblyopia after patching therapy, oral levodopa while continuing to patch 2 hours daily does not produce a clinically or statistically meaningful improvement in VA compared with placebo and patching.

Comment in

PMID:
25676904
PMCID:
PMC4414716
DOI:
10.1016/j.ophtha.2015.01.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center